|
Delayed
London S.E.
14:27:34 07/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 0.1567 GBX | -5.03% |
|
-1.14% | -38.55% |
| 08-25 | Nuformix hires ex-Zeus Capital joint CEO Metcalfe as chair | AN |
| 08-25 | Nuformix Names New Nonexecutive Chairman | MT |
| Market Cap | 4.31M 5.82M 5.01M 4.71M 8.06M 550M 8.08M 55.7M 21.61M 282M 21.86M 21.39M 909M | P/E 2024 |
-0.13x | P/E 2025 | -5.88x |
|---|---|---|---|---|---|
| Enterprise Value | 4.21M 5.69M 4.9M 4.61M 7.87M 537M 7.89M 54.44M 21.13M 276M 21.37M 20.9M 888M | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
94.63% | Yield 2024 * |
-
| Yield 2025 | - |
London S.E.GBX
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| LVRT | Delayed | |
Deutsche Boerse AG
| 1RT | Delayed | |
|
Börse Stuttgart
| 1RT | Delayed |
| 23/05/25 | Nuformix : Prospectus | PU |
| 05/10/23 | Nuformix to fund its unlicensed programs with NXP001 windfall | AQ |
| 20/12/22 | Nuformix hoping to "initiate discussions with major pharma" in 2023 | AQ |
| 20/12/22 | Nuformix hoping to 'initiate discussions with major pharma' in 2023 | EQ |
| 18/02/20 | Nuformix : Appointment of Dr Karl Keegan | PU |
| 1 day | -5.03% | ||
| 1 week | -1.14% | ||
| Current month | -5.03% | ||
| 1 month | +18.71% | ||
| 3 months | -7.00% | ||
| 6 months | -39.73% | ||
| Current year | -38.55% |
| 1 week | 0.15 |  | 0.17 |
| 1 month | 0.12 | | 0.2 |
| Current year | 0.12 | | 0.4 |
| 1 year | 0.09 | | 0.56 |
| 3 years | 0.04 | | 0.56 |
| 5 years | 0.04 | | 1.93 |
| 10 years | 0.04 | | 14.89 |
| Manager | Title | Age | Since |
|---|---|---|---|
Shaun Zulafqar
SEC | Corporate Secretary | - | 29/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 61 | 02/12/2020 | |
Timothy Metcalfe
CHM | Chairman | 54 | 01/09/2026 |
Daniel Gooding
BRD | Director/Board Member | 53 | 01/07/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 11/5/24 A | Free | Director | 22,000,000 | 2.6852% | ||
| 11/5/24 A | Free | Chairman | 22,000,000 | 2.6852% | ||
| 11/5/24 A | Free | Founder | 12,000,000 | 1.4646% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.03% | -1.14% | +64.95% | -43.02% | 5.82M | |
| -0.88% | -2.15% | +58.05% | +105.26% | 1,024B | |
| -1.15% | +2.68% | +54.25% | +74.19% | 663B | |
| -1.44% | +0.38% | +20.65% | +76.13% | 453B | |
| -0.62% | +0.62% | +31.43% | +38.32% | 352B | |
| -2.55% | +2.48% | +23.46% | +42.53% | 304B | |
| +1.53% | +1.98% | +1.91% | +12.70% | 252B | |
| -1.55% | +1.11% | +54.15% | +75.59% | 236B | |
| -0.13% | +2.21% | -13.86% | -55.81% | 206B | |
| -0.15% | +3.65% | +31.24% | +103.39% | 187B | |
| Average | -1.17% | +1.14% | +32.62% | +42.93% | 367.84B | |
| Weighted average by Cap. | -0.89% | +0.62% | +37.87% | +67.13% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -3.64M -4.92M -4.24M -3.99M -6.81M -465M -6.83M -47.11M -18.28M -239M -18.49M -18.09M -768M | -653K -882K -759K -714K -1.22M -83.31M -1.22M -8.44M -3.28M -42.74M -3.31M -3.24M -138M |
| Net Debt | -20.21K -27.33K -23.51K -22.12K -37.81K -2.58M -37.91K -261K -101K -1.32M -103K -100K -4.26M | -97.55K -132K -113K -107K -182K -12.45M -183K -1.26M -490K -6.39M -495K -484K -20.58M |
Employees
3
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 07/09/26 | GBX 0.1567 | -5.03% | 3,104,342 |
| 04/09/26 | GBX 0.1650 | 0.00% | 9,036,108 |
| 03/09/26 | GBX 0.1650 | 0.00% | 2,454,404 |
| 02/09/26 | GBX 0.1650 | +4.10% | 10,006,930 |
| 01/09/26 | GBX 0.1585 | -3.94% | 27,739,954 |
- Stock Market
- Stocks
- LVRT Stock
Select your edition
All financial news and data tailored to specific country editions
